Cignarelli Angelo, Santi Daniele, Genchi Valentina Annamaria, Conte Eleonora, Giordano Fiorella, Di Leo Simona, Natalicchio Annalisa, Laviola Luigi, Giorgino Francesco, Perrini Sebastio
Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Andrology. 2023 Feb;11(2):234-244. doi: 10.1111/andr.13357. Epub 2022 Dec 14.
The very low-calorie ketogenic diet (VLCKD) represents an opportunity to attain clinically relevant weight loss in obese patients. Functional hypogonadism represents a frequent hormonal disorder associated with obesity and visceral fat accumulation characterised by low testosterone levels and subnormal luteinising hormone (LH) levels.
To evaluate the early effects of VLCKD on serum total testosterone (TT) levels in non-diabetic obese patients.
Twenty-two obese male patients (mean age 39.3 ± 11.7 years, mean body mass index (BMI) 38.2 ± 6.4 kg/m ) were enrolled and treated for 28 days with VLCKD. Anthropometric and hormonal variables were assessed before, during and after diet intervention.
After 7 and 28 days on a VLCKD, a significant and persistent reduction in body weight, BMI, fat mass, blood glucose, insulin and homeostasis model assessment index was observed compared with baseline. TT significantly increased after 7 days (+35 ± 64 ng/dl) and 28 days (+74 ± 97 ng/dl) on a VLCKD. In addition to TT, a significant increase in serum sex hormone-binding globulin levels was observed after 7 (+2.1 ± 4.1) and 28 days (+7.7 ± 10.0). However, both calculated free testosterone and LH did not change after 7 or 28 days of VLCKD. Following cessation of VLCKD, hypogonadal subjects achieved a higher percentage of total weight loss (8.5% ± 1.5%), a greater reduction in weight (-9.94 ± 1.66 kg), fat mass (-7 ± 2.1 kg) and waist circumference (-6.31 ± 2.65 cm) and a greater improvement in glycaemia (-8.75 ± 10.92 mg/dl) as compared with eugonadal subjects. Furthermore, hypogonadal subjects exhibited a trend of higher TT increase (+98.12 ± 71.51 ng/dl) as compared with eugonadal subjects.
VLCKD results in rapid improvements in TT levels associated with weight loss in male obese non-diabetic subjects, particularly in the presence of obesity-related hypogonadism.
极低热量生酮饮食(VLCKD)为肥胖患者实现具有临床意义的体重减轻提供了契机。功能性性腺功能减退是一种常见的激素紊乱疾病,与肥胖和内脏脂肪堆积相关,其特征为睾酮水平低和促黄体生成素(LH)水平低于正常。
评估VLCKD对非糖尿病肥胖患者血清总睾酮(TT)水平的早期影响。
纳入22例肥胖男性患者(平均年龄39.3±11.7岁,平均体重指数(BMI)38.2±6.4kg/m²),采用VLCKD治疗28天。在饮食干预前、期间和之后评估人体测量和激素变量。
与基线相比,采用VLCKD治疗7天和28天后,体重、BMI、脂肪量、血糖、胰岛素和稳态模型评估指数均出现显著且持续的下降。采用VLCKD治疗7天(+35±64ng/dl)和28天(+74±97ng/dl)后,TT显著升高。除TT外,治疗7天(+2.1±4.1)和28天(+7.7±10.0)后,血清性激素结合球蛋白水平也显著升高。然而,计算得出的游离睾酮和LH在VLCKD治疗7天或28天后均未发生变化。停用VLCKD后,性腺功能减退的受试者在总体重减轻百分比(8.5%±1.5%)、体重(-9.94±1.66kg)、脂肪量(-7±2.1kg)和腰围(-6.31±2.65cm)下降幅度以及血糖改善程度(-8.75±10.92mg/dl)方面均高于性腺功能正常的受试者。此外,与性腺功能正常的受试者相比,性腺功能减退的受试者的TT升高趋势更为明显(+98.12±71.51ng/dl)。
VLCKD可使男性肥胖非糖尿病受试者的TT水平迅速改善,并伴有体重减轻,在存在肥胖相关性腺功能减退的情况下尤其如此。